PMID- 22355046
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20211021
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 30
IP  - 9
DP  - 2012 Mar 20
TI  - Variation of second cancer risk by family history of retinoblastoma among 
      long-term survivors.
PG  - 950-7
LID - 10.1200/JCO.2011.37.0239 [doi]
AB  - PURPOSE: To evaluate the risk of second cancer (SC) in long-term survivors of 
      retinoblastoma (Rb) according to classification of germline mutation, based on 
      family history of Rb and laterality. PATIENTS AND METHODS: We assembled a cohort 
      of 1,852 1-year survivors of Rb (bilateral, n = 1,036; unilateral, n = 816). SCs 
      were ascertained by medical records and self-reports and confirmed by pathology 
      reports. Classification of RB1 germline mutation, inherited or de novo, was 
      inferred by laterality of Rb and positive family history of Rb. Standardized 
      incidence ratios and cumulative incidence for all SCs combined and for soft 
      tissue sarcomas, bone cancers, and melanoma were calculated. The influence of 
      host- and therapy-related risk factors for SC was assessed by Poisson regression 
      for bilateral survivors. RESULTS: We observed a relative risk (RR) of 1.37 (95% 
      CI, 1.00 to 1.86) for SCs in bilateral survivors associated with a family history 
      of Rb, adjusted for treatment, age, and length of follow-up. The risk for 
      melanoma was significantly elevated for survivors with a family history of Rb 
      (RR, 3.08; 95% CI, 1.23 to 7.16), but risks for bone or soft tissue sarcomas were 
      not elevated. The cumulative incidence of SCs 50 years after diagnosis of 
      bilateral Rb, with adjustment for competing risk of death, was significantly 
      higher for survivors with a family history (47%; 95% CI, 35% to 59%) than 
      survivors without a family history (38%; 95% CI, 32% to 44%; P = .004). 
      CONCLUSION: Rb survivors with bilateral disease and an inherited germline 
      mutation are at slightly higher risk of an SC compared with those with a de novo 
      germline mutation, in particular melanoma, perhaps because of shared genetic 
      alterations.
FAU - Kleinerman, Ruth A
AU  - Kleinerman RA
AD  - National Cancer Institute, National Institutes of Health, Department of Health 
      and Human Services, Rockville, MD, USA. Kleinerr@mail.nih.gov
FAU - Yu, Chu-Ling
AU  - Yu CL
FAU - Little, Mark P
AU  - Little MP
FAU - Li, Yi
AU  - Li Y
FAU - Abramson, David
AU  - Abramson D
FAU - Seddon, Johanna
AU  - Seddon J
FAU - Tucker, Margaret A
AU  - Tucker MA
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20120221
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Retinoblastoma Protein)
SB  - IM
CIN - J Clin Oncol. 2012 Aug 20;30(24):3028; author reply 3028-9. PMID: 22802309
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - *Genetic Predisposition to Disease
MH  - Germ-Line Mutation/*genetics
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Maryland/epidemiology
MH  - Middle Aged
MH  - Neoplasms, Second Primary/epidemiology/*etiology/mortality
MH  - Prognosis
MH  - Retinal Neoplasms/*complications/genetics/mortality
MH  - Retinoblastoma/*complications/genetics/mortality
MH  - Retinoblastoma Protein/*genetics
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Rate
MH  - *Survivors
MH  - Young Adult
PMC - PMC3341108
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2012/02/23 06:00
MHDA- 2012/05/09 06:00
PMCR- 2013/03/20
CRDT- 2012/02/23 06:00
PHST- 2012/02/23 06:00 [entrez]
PHST- 2012/02/23 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
PHST- 2013/03/20 00:00 [pmc-release]
AID - JCO.2011.37.0239 [pii]
AID - 70239 [pii]
AID - 10.1200/JCO.2011.37.0239 [doi]
PST - ppublish
SO  - J Clin Oncol. 2012 Mar 20;30(9):950-7. doi: 10.1200/JCO.2011.37.0239. Epub 2012 
      Feb 21.